Drug intelligence / Profile preview

[11C]SY08

Development stage: Phase 1
Lead developer: The Schwartz Center for Compassionate Healthcare
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A PET radiotracer designed to bind to aggregated alpha-synuclein (αS) in the brain. It is being evaluated for use in imaging studies of patients with synucleinopathies including Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies.

Other names: 4-methoxy-N-(4-(3-(pyridin-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)benzamide

Targets

α-syn fibril (Alpha-synuclein (SNCA))

Beyond the preview

Go deeper on [11C]SY08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [11C]SY08.

Explore the full profile